SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack
Spectrometry for TIA Rapid Assessment (SpecTRA) Project: Study 2-Validation of Clinical Features and Protein Biomarkers
Sponsor: Andrew Penn
Listed as NCT03070067, this observational or N/A phase trial focuses on TIA and remains completed. Sponsored by Andrew Penn, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 7 earlier versions
-
Sep 2020 — Nov 2020 [monthly]
Completed
-
Jun 2018 — Sep 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Sep 2017 — Apr 2018 [monthly]
Completed NA
Status: Recruiting → Completed
-
Aug 2017 — Sep 2017 [monthly]
Recruiting NA
-
Mar 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Andrew Penn
- British Columbia Centre for Disease Control
- Bruker Daltonics
- Genome Alberta
- Genome British Columbia
- Genome Canada
- Heart and Stroke Foundation of Canada
- LifeLabs
- Stroke Services BC
- Vancouver Island Health Authority
For direct contact, visit the study record on ClinicalTrials.gov .